PDGF and the progression of renal disease

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Boor, Peter ^a,b   Ostendorf, Tammo ^a   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

chronic kidney disease; fibroblasts; fibrosis; mesangial cells; platelet derived growth factors

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL PRACTICE; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERTENSION; KIDNEY DEVELOPMENT; KIDNEY DISEASE; KIDNEY FIBROSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION; SIGNAL TRANSDUCTION;

CHRONIC KIDNEY DISEASE; FIBROBLASTS; FIBROSIS; MESANGIAL CELLS; PLATELET-DERIVED GROWTH FACTORS;

ANIMALS; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; PLATELET-DERIVED GROWTH FACTOR;

EID: 84893838719     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft273     Document Type: Review

References (89)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
2. Boor P, Ostendorf T, Floege J. Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643-656
3. Samuels JA, Molony DA. Randomized controlled trials in nephrology: State of the evidence and critiquing the evidence. Adv Chronic Kidney Dis 2012; 19: 40-46
4. Ross R, Glomset J, Kariya B et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974; 71: 1207-1210
5. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet- derived growth factor. Physiol Rev 1999; 79: 1283-1316
6. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004; 15: 215-228
7. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004; 15: 237-254
8. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-273
9. Boor P, Floege J. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 2011; 38: 391-400
10. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004; 15: 205-213
11. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19: 12-23
12. Ostendorf T, Eitner F, Floege J. The PDGF family in renal fibrosis. Pediatr Nephrol 2012; 27: 1041-1050
13. Fredriksson L, Li H, Eriksson U. The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004; 15: 197-204
14. Gaboriaud C, Gregory-Pauron L, Teillet F et al. Structure and properties of the Ca(2+)-binding CUB domain, a widespread ligand-recognition unit involved in major biological functions. Biochem J 2011; 439: 185-193
15. Seikrit C, Henkel C, van Roeyen CR et al. Biological responses to PDGFAA versus PDGF-CC in renal fibroblasts. Nephrol Dial Transplant 2013; 28: 889-900
16. van Roeyen CR, Ostendorf T, Denecke B et al. Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. Kidney Int 2006; 69: 1393-1402
17. Boor P, van Roeyen CR, Kunter U et al. PDGF-C mediates glomerular capillary repair. Am J Pathol 2010; 177: 58-69
18. Li X, Tjwa M, Moons L et al. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 2005; 115: 118-127
19. Liu G, Changsirikulchai S, Hudkins KL et al. Identification of plateletderived growth factor D in human chronic allograft nephropathy. Hum Pathol 2008; 39: 393-402
20. Eitner F, Ostendorf T, Kretzler M et al. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol 2003; 14: 1145-1153
21. Chen YT, Chang FC, Wu CF et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 2011; 80: 1170-1181
22. Hudkins KL, Gilbertson DG, Carling M et al. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 2004; 15: 286-298
23. Taneda S, Hudkins KL, Topouzis S et al. Obstructive uropathy in mice and humans: Potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 2003; 14: 2544-2555
24. Eitner F, Bucher E, van Roeyen C et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008; 19: 281-289
25. Bjarnegard M, Enge M, Norlin J et al. Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development 2004; 131: 1847-1857
26. Hellstrom M, Kalen M, Lindahl P et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999; 126: 3047-3055
27. Lindahl P, Hellstrom M, Kalen M et al. Paracrine PDGF-B/PDGF-Rbeta signaling controls mesangial cell development in kidney glomeruli. Development 1998; 125: 3313-3322
28. Leveen P, Pekny M, Gebre-Medhin S et al. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994; 8: 1875-1887
29. Bostrom H, Willetts K, Pekny M et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 1996; 85: 863-873
30. Ding H, Wu X, Bostrom H et al. A specific requirement for PDGF-C in palate formation and PDGFR-Alpha signaling. Nat Genet 2004; 36: 1111-1116
31. Li X, Ponten A, Aase K et al. PDGF-C is a new protease-Activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000; 2: 302-309
32. Ricono JM, Wagner B, Gorin Y et al. PDGF receptor-{beta} modulates metanephric mesenchyme chemotaxis induced by PDGF AA. Am J Physiol Renal Physiol 2009; 296: F406-F417
33. Nakagawa T, Izumino K, Ishii Y et al. Roles of PDGF receptor-beta in the structure and function of postnatal kidney glomerulus. Nephrol Dial Transplant 2011; 26: 458-468
34. Floege J, van Roeyen C, Boor P et al. The role of PDGF-D in mesangioproliferative glomerulonephritis. Contrib Nephrol 2007; 157: 153-158
35. Ostendorf T, van Roeyen CR, Peterson JD et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2003; 14: 2237-2247
36. van Roeyen CR, Eitner F, Boor P et al. Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int 2011; 80: 1292-1305
37. Nakamura H, Isaka Y, Tsujie M et al. Electroporation-mediated PDGF receptor- IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int 2001; 59: 2134-2145
38. Boor P, Konieczny A, Villa L et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 2007; 22: 1323-1331
39. Ostendorf T, Kunter U, Grone HJ et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001; 12: 909-918
40. Ostendorf T, Rong S, Boor P et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 1054-1062
41. Eitner F, Ostendorf T, Van Roeyen C et al. Expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. J Am Soc Nephrol 2002; 13: 910-917
42. van Roeyen CR, Boor P, Borkham-Kamphorst E et al. A novel, dual role of CCN3 in experimental glomerulonephritis: Pro-Angiogenic and antimesangioproliferative effects. Am J Pathol 2012; 180: 1979-1990
43. van Roeyen CR, Eitner F, Scholl T et al. CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 2008; 73: 86-94
44. Riser BL, Najmabadi F, Perbal B et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 2009; 174: 1725-1734
45. van Roeyen CR, Zok S, Pruessmeyer J et al. Growth arrest-specific protein 1 is a novel endogenous inhibitor of glomerular cell activation and proliferation. Kidney Int 2013; 83: 251-263
46. Boor P, Eitner F, Cohen CD et al. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrol Dial Transplant 2009; 24: 2755-2762
47. Rong ZH, Wang C, Hao J et al. Expression and clinical implication of platelet-derived growth factor-D and platelet-derived growth factor-beta in childhood IgA nephropathy. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008; 20: 275-278
48. Bicanski B, WenderdelM, Mertens PR et al. PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. Clin Nephrol 2007; 67: 65-72
49. Matsuda M, Shikata K, Makino H et al. Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis. Am J Nephrol 1997; 17: 25-31
50. Waldherr R, Noronha IL, Niemir Z et al. Expression of cytokines and growth factors in human glomerulonephritides. Pediatr Nephrol 1993; 7: 471-478
51. Fujigaki Y, Sun DF, Fujimoto T et al. Mechanisms and kinetics of Bowman's epithelial-myofibroblast transdifferentiation in the formation of glomerular crescents. Nephron 2002; 92: 203-212
52. Fujigaki Y, Sun DF, Fujimoto T et al. Cytokines and cell cycle regulation in the fibrous progression of crescent formation in antiglomerular basement membrane nephritis of WKY rats. Virchows Arch 2001; 439: 35-45
53. Iyoda M, Shibata T, Kawaguchi M et al. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int 2009; 75: 1060-1070
54. Shinkai Y, Cameron JS. Trial of platelet-derived growth factor antagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit. Br J Exp Pathol 1987; 68: 847-852
55. Iyoda M, Shibata T, Wada Y et al. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrol Dial Transplant 2013; 28: 576-584
56. Gesualdo L, Di Paolo S, Milani S et al. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J Clin Invest 1994; 94: 50-58
57. Zoja C, Corna D, Rottoli D et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 2006; 70: 97-103
58. Sadanaga A, Nakashima H, Masutani K et al. Amelioration of autoimmune nephritis by imatinib inMRL/lpr mice. Arthritis Rheum 2005; 52: 3987-3996
59. Iyoda M, Hudkins KL, Becker-Herman S et al. Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J Am Soc Nephrol 2009; 20: 68-77
60. Taneda S, Hudkins KL, Cui Y et al. Growth factor expression in a murine model of cryoglobulinemia. Kidney Int 2003; 63: 576-590
61. Li X, Kumar A, Zhang F et al. VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget 2010; 1: 309-314
62. Antoniu SA. Targeting PDGF pathway in pulmonary arterial hypertension. Expert Opin Ther Targets 2012; 16: 1055-1063
63. ten Freyhaus H, Dumitrescu D, Berghausen E et al. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 2012; 21: 119-134
64. Ikeda M, Morita C, Mizuno M et al. PDGF-BB decreases systolic blood pressure through an increase in macrovascular compliance in rats. Am J Physiol 1997; 273(4 Pt 2): H1719-H1726
65. Schellings MW, Baumann M, van Leeuwen RE et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006; 47: 467-474
66. Graciano ML, Mitchell KD. Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 2012; 302: F60-F69
67. Kishioka H, Fukuda N, Wen-Yang H et al. Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in strokeprone spontaneously hypertensive rats. Am J Hypertens 2001; 14(5 Pt 1): 439-445
68. Uehara G, Suzuki D, Toyoda M et al. Glomerular expression of plateletderived growth factor (PDGF)-A, -B chain and PDGF receptor-Alpha, -beta in human diabetic nephropathy. Clin Exp Nephrol 2004; 8: 36-42
69. Lassila M, Jandeleit-Dahm K, Seah KK et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005; 16: 363-373
70. Suzuki H, Usui I, Kato I et al. Deletion of platelet-derived growth factor receptor- beta improves diabetic nephropathy in Ca(2)(+)/calmodulin- dependent protein kinase IIalpha (Thr286Asp) transgenic mice. Diabetologia 2011; 54: 2953-2962
71. Chen H, Gu X, Liu Y et al. PDGF signalling controls age-dependent proliferation in pancreatic beta-cells. Nature 2011; 478: 349-355
72. Tang WW, Ulich TR, Lacey DL et al. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 1996; 148: 1169-1180
73. Floege J, Eng E, Young BA et al. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 1993; 92: 2952-2962
74. Olson LE, Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 2009; 16: 303-313
75. Martin IV, Borkham-Kamphorst E, Zok S et al. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am J Pathol 2013; 182: 107-117
76. Kang DH, Hughes J, Mazzali M et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12: 1448-1457
77. Ren S, Johnson BG, Kida Y et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA 2013; 110: 1440-1445
78. Liu N, Tolbert E, Pang M et al. Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1064-1075
79. Liu N, Tolbert E, Ponnusamy M et al. Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 2011; 338: 758-766
80. Nakagawa T, Sasahara M, Haneda M et al. Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury. Am J Pathol 1999; 155: 1689-1699
81. Hawthorne T, Giot L, Blake L et al. A phase I study of CR002, a fullyhuman monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther 2008; 46: 236-244
82. Lewis NL, Lewis LD, Eder JP et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific plateletderived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 2009; 27: 5262-5269
83. Jayson GC, Parker GJ, Mullamitha S et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005; 23: 973-981
84. Margolis DJ, Morris LM, Papadopoulos M et al. Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease. Mol Ther 2009; 17: 1822-1829
85. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916
86. Berman E, Nicolaides M, Maki RG et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013
87. Shen J, Vil MD, Prewett M et al. Development of a fully human anti- PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 2009; 11: 594-604
88. Boor P, Sebekova K, Ostendorf T et al. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007; 22: 3391-3407
89. Khanna D, Saggar R, Mayes MD et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosisassociated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540-3546